-
公开(公告)号:EP2968993A1
公开(公告)日:2016-01-20
申请号:EP14765468.5
申请日:2014-03-14
申请人: Purdue Pharma L.P.
IPC分类号: A61P25/04
CPC分类号: A61K9/2081 , A61K9/1652 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2095 , A61K9/2846 , A61K9/4808 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K9/5084 , A61K9/5089 , A61K31/485 , A61K47/10 , A61K47/32 , A61K47/38
摘要: Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material.
摘要翻译: 在某些实施方案中公开了包含多个颗粒的固体口服剂型,每个颗粒包含(i)包含易被滥用的活性剂和内部助粘剂的核心,其中所述核心(i)分散在包含 控释材料或(ii)涂有控释材料。 剂型还可以包含耐醇材料。
-
公开(公告)号:EP2968993B1
公开(公告)日:2019-07-17
申请号:EP14765468.5
申请日:2014-03-14
申请人: Purdue Pharma L.P.
IPC分类号: A61P25/04
-